Beijing Sun-Novo Pharmaceutical Research Co., Ltd. announced a private placement of common shares on November 7, 2022. The transaction has been approved at the 22nd meeting of the company's first board of directors. The transaction will include participation from not more than 35 investors.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
Equities
688621
CNE100005139
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43 CNY | +0.70% | -3.59% | -38.35% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-38.35% | 66Cr | |
+16.59% | 4.55TCr | |
-9.89% | 3.85TCr | |
+38.08% | 3.81TCr | |
+27.12% | 3.07TCr | |
-8.64% | 2.6TCr | |
+11.81% | 2.59TCr | |
+45.08% | 1.41TCr | |
+32.85% | 1.27TCr | |
-7.19% | 1.13TCr |
- Stock Market
- Equities
- 688621 Stock
- News Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
- Beijing Sun-Novo Pharmaceutical Research Co., Ltd. announced that it expects to receive CNY 1 billion in funding